glofitamab DLBCL
Selected indexed studies
- Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (N Engl J Med, 2022) [PMID:36507690]
- Engaging results with glofitamab in DLBCL. (Nat Rev Clin Oncol, 2023) [PMID:36600006]
- Glofitamab: First Approval. (Drugs, 2023) [PMID:37285013]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (2022) pubmed
- Glofitamab: First Approval. (2023) pubmed
- New bispecific antibodies in diffuse large B-cell lymphoma. (2025) pubmed
- Engaging results with glofitamab in DLBCL. (2023) pubmed
- Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. (2025) pubmed
- Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study. (2025) pubmed
- Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study. (2025) pubmed
- Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. (2022) pubmed
- PMID:38588352 (2024) pubmed
- Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study. (2025) pubmed